Cargando…

Validated LC‐MS/MS method of Sphingosine 1‐phosphate quantification in human serum for evaluation of response to radiotherapy in lung cancer

BACKGROUND: Sphingosine 1‐phosphate (S1P), a bioactive lipid, has been shown to mediate cancer processes. Therefore, accurate qualitative and quantitative determination is essential. The current assay method is still cumbersome to be of practical use worldwide and the aim of this study was therefore...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Xiaohui, Chen, Haisheng, Chen, Guanxuan, Duan, Cunxian, Fan, Qing, Li, Hui, Wang, Yanhong, Li, Zhijun, Shi, Wenna, Liu, Yuguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262919/
https://www.ncbi.nlm.nih.gov/pubmed/32233070
http://dx.doi.org/10.1111/1759-7714.13409
_version_ 1783540715523932160
author Tang, Xiaohui
Chen, Haisheng
Chen, Guanxuan
Duan, Cunxian
Fan, Qing
Li, Hui
Wang, Yanhong
Li, Zhijun
Shi, Wenna
Liu, Yuguo
author_facet Tang, Xiaohui
Chen, Haisheng
Chen, Guanxuan
Duan, Cunxian
Fan, Qing
Li, Hui
Wang, Yanhong
Li, Zhijun
Shi, Wenna
Liu, Yuguo
author_sort Tang, Xiaohui
collection PubMed
description BACKGROUND: Sphingosine 1‐phosphate (S1P), a bioactive lipid, has been shown to mediate cancer processes. Therefore, accurate qualitative and quantitative determination is essential. The current assay method is still cumbersome to be of practical use worldwide and the aim of this study was therefore to develop a fast, accurate, precise and efficient LC‐MS/MS method for targeted analyses of S1P in serum samples. METHODS: Liquid chromatography‐tandem mass spectrometry (LC‐MS/MS) is an established method used for monitoring and analyzing S1P levels in serum. We determined the level of serum S1P in 256 patients with lung cancer and 36 healthy donors, and used Spearman';s rank correlation analysis to evaluate the difference in serum S1P levels between radiotherapy and nonradiotherapy patients. RESULTS: Standard curves were linear over ranges of 25–600 ng/mL for S1P with correlation coefficient (r(2)) greater than 0.9996. The lower limit of quantifications (LLOQs) was 25 ng/mL. The intra‐ and interbatch precisions and accuracy was less than 10% for S1P. The recoveries of the method were found to be 80%–98%. Serum S1P levels in healthy donors were different from those in patients (P < 0.001). Of 256 lung cancer patients, 124 (48.4%) received radiotherapy and were identified to have concomitant low serum S1P levels (222.13 ± 48.63), whereas 132 (51.6%) who had not received radiotherapy were identified to have high levels (315.16 ± 51.06). The serum S1P levels were therefore associated with radiotherapy (Spearman's Rho = −0.653, P < 0.001). CONCLUSIONS: Our results indicated that this new LC‐MS/MS method is rapid, sensitive, specific and reliable for the quantification of S1P levels in serum samples. The level of S1P in serum samples of patients with lung cancer who received radiotherapy was significantly lower than that in patients who did not receive radiotherapy. KEY POINTS: An improved method was established to quantify S1P levels in human serum by LC‐MS/MS, which enabled the change in serum S1P levels in lung cancer patients to be monitored, in combination with radiotherapy, and their clinical significance to be analyzed.
format Online
Article
Text
id pubmed-7262919
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-72629192020-06-03 Validated LC‐MS/MS method of Sphingosine 1‐phosphate quantification in human serum for evaluation of response to radiotherapy in lung cancer Tang, Xiaohui Chen, Haisheng Chen, Guanxuan Duan, Cunxian Fan, Qing Li, Hui Wang, Yanhong Li, Zhijun Shi, Wenna Liu, Yuguo Thorac Cancer Original Articles BACKGROUND: Sphingosine 1‐phosphate (S1P), a bioactive lipid, has been shown to mediate cancer processes. Therefore, accurate qualitative and quantitative determination is essential. The current assay method is still cumbersome to be of practical use worldwide and the aim of this study was therefore to develop a fast, accurate, precise and efficient LC‐MS/MS method for targeted analyses of S1P in serum samples. METHODS: Liquid chromatography‐tandem mass spectrometry (LC‐MS/MS) is an established method used for monitoring and analyzing S1P levels in serum. We determined the level of serum S1P in 256 patients with lung cancer and 36 healthy donors, and used Spearman';s rank correlation analysis to evaluate the difference in serum S1P levels between radiotherapy and nonradiotherapy patients. RESULTS: Standard curves were linear over ranges of 25–600 ng/mL for S1P with correlation coefficient (r(2)) greater than 0.9996. The lower limit of quantifications (LLOQs) was 25 ng/mL. The intra‐ and interbatch precisions and accuracy was less than 10% for S1P. The recoveries of the method were found to be 80%–98%. Serum S1P levels in healthy donors were different from those in patients (P < 0.001). Of 256 lung cancer patients, 124 (48.4%) received radiotherapy and were identified to have concomitant low serum S1P levels (222.13 ± 48.63), whereas 132 (51.6%) who had not received radiotherapy were identified to have high levels (315.16 ± 51.06). The serum S1P levels were therefore associated with radiotherapy (Spearman's Rho = −0.653, P < 0.001). CONCLUSIONS: Our results indicated that this new LC‐MS/MS method is rapid, sensitive, specific and reliable for the quantification of S1P levels in serum samples. The level of S1P in serum samples of patients with lung cancer who received radiotherapy was significantly lower than that in patients who did not receive radiotherapy. KEY POINTS: An improved method was established to quantify S1P levels in human serum by LC‐MS/MS, which enabled the change in serum S1P levels in lung cancer patients to be monitored, in combination with radiotherapy, and their clinical significance to be analyzed. John Wiley & Sons Australia, Ltd 2020-03-31 2020-06 /pmc/articles/PMC7262919/ /pubmed/32233070 http://dx.doi.org/10.1111/1759-7714.13409 Text en © 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Tang, Xiaohui
Chen, Haisheng
Chen, Guanxuan
Duan, Cunxian
Fan, Qing
Li, Hui
Wang, Yanhong
Li, Zhijun
Shi, Wenna
Liu, Yuguo
Validated LC‐MS/MS method of Sphingosine 1‐phosphate quantification in human serum for evaluation of response to radiotherapy in lung cancer
title Validated LC‐MS/MS method of Sphingosine 1‐phosphate quantification in human serum for evaluation of response to radiotherapy in lung cancer
title_full Validated LC‐MS/MS method of Sphingosine 1‐phosphate quantification in human serum for evaluation of response to radiotherapy in lung cancer
title_fullStr Validated LC‐MS/MS method of Sphingosine 1‐phosphate quantification in human serum for evaluation of response to radiotherapy in lung cancer
title_full_unstemmed Validated LC‐MS/MS method of Sphingosine 1‐phosphate quantification in human serum for evaluation of response to radiotherapy in lung cancer
title_short Validated LC‐MS/MS method of Sphingosine 1‐phosphate quantification in human serum for evaluation of response to radiotherapy in lung cancer
title_sort validated lc‐ms/ms method of sphingosine 1‐phosphate quantification in human serum for evaluation of response to radiotherapy in lung cancer
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262919/
https://www.ncbi.nlm.nih.gov/pubmed/32233070
http://dx.doi.org/10.1111/1759-7714.13409
work_keys_str_mv AT tangxiaohui validatedlcmsmsmethodofsphingosine1phosphatequantificationinhumanserumforevaluationofresponsetoradiotherapyinlungcancer
AT chenhaisheng validatedlcmsmsmethodofsphingosine1phosphatequantificationinhumanserumforevaluationofresponsetoradiotherapyinlungcancer
AT chenguanxuan validatedlcmsmsmethodofsphingosine1phosphatequantificationinhumanserumforevaluationofresponsetoradiotherapyinlungcancer
AT duancunxian validatedlcmsmsmethodofsphingosine1phosphatequantificationinhumanserumforevaluationofresponsetoradiotherapyinlungcancer
AT fanqing validatedlcmsmsmethodofsphingosine1phosphatequantificationinhumanserumforevaluationofresponsetoradiotherapyinlungcancer
AT lihui validatedlcmsmsmethodofsphingosine1phosphatequantificationinhumanserumforevaluationofresponsetoradiotherapyinlungcancer
AT wangyanhong validatedlcmsmsmethodofsphingosine1phosphatequantificationinhumanserumforevaluationofresponsetoradiotherapyinlungcancer
AT lizhijun validatedlcmsmsmethodofsphingosine1phosphatequantificationinhumanserumforevaluationofresponsetoradiotherapyinlungcancer
AT shiwenna validatedlcmsmsmethodofsphingosine1phosphatequantificationinhumanserumforevaluationofresponsetoradiotherapyinlungcancer
AT liuyuguo validatedlcmsmsmethodofsphingosine1phosphatequantificationinhumanserumforevaluationofresponsetoradiotherapyinlungcancer